Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Life Molecular Imaging SA

www.life-mi.com

Latest From Life Molecular Imaging SA

Alzheimer's Prevention: The Next Big Idea For Fixing Drug Trial Failures

Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.

Neurology Clinical Trials

Investors Find Opportunity In Tau-Targeting Biopharmas

Tau-targeting Alzheimer's candidates, though historically rejected in favor of amyloid-beta targeting ones, have gained increasing interest from investors and larger pharma companies.

BioPharmaceutical Deals

Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty

With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.

Medical Device Innovation

Eli Lilly Lawsuit Challenges CMS Coverage Standard For Alzheimer's Diagnostic

A lawsuit filed by Medicare beneficiaries with support from the manufacturer of an imaging agent approved to help evaluate adults for Alzheimer’s disease says diagnostic scans should not be required to show a change in disease management or outcomes to qualify for Medicare coverage. CMS limits coverage to the beta-amyloid plaque to use in clinical trials, and only one trial has been approved.

Medical Device Reimbursement
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Piramal Imaging SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Life Molecular Imaging SA
  • Senior Management
  • Ludger Dinkelborg, Mng. Dir.
    Andrew Stephens, MD, PhD, CMO
  • Contact Info
  • Life Molecular Imaging SA
    Route de l’Ecole 13
    Matran, 1753
    Switzerland
UsernamePublicRestriction

Register